Atossa Competitors
| ATOS Stock | USD 5.33 0.20 3.62% |
Atossa Genetics vs Coya Therapeutics Correlation
Poor diversification
The correlation between Atossa Genetics and COYA is 0.76 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Atossa Genetics and COYA in the same portfolio, assuming nothing else is changed.
Moving together with Atossa Stock
Moving against Atossa Stock
| 0.77 | QIPT | Quipt Home Medical Earnings Call This Week | PairCorr |
| 0.77 | VMD | Viemed Healthcare | PairCorr |
| 0.76 | 4DX | 4DMEDICAL | PairCorr |
| 0.47 | AMS | Advanced Medical Sol | PairCorr |
| 0.31 | IMDX | Insight Molecular Symbol Change | PairCorr |
Atossa Genetics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Atossa Genetics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Atossa and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Atossa Genetics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Atossa Stock performing well and Atossa Genetics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Atossa Genetics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ONCY | 3.90 | (0.37) | 0.00 | (0.12) | 0.00 | 8.55 | 27.46 | |||
| TVGN | 4.80 | (1.13) | 0.00 | (0.36) | 0.00 | 10.00 | 26.81 | |||
| GLSI | 6.25 | 1.86 | 0.28 | 1.08 | 5.78 | 19.77 | 36.51 | |||
| TIL | 3.98 | (0.98) | 0.00 | (1.54) | 0.00 | 6.59 | 55.58 | |||
| IMMX | 4.71 | 0.89 | 0.19 | 0.84 | 4.24 | 14.88 | 28.79 | |||
| WHWK | 3.46 | 0.40 | 0.11 | 0.38 | 3.47 | 6.98 | 21.49 | |||
| CLNN | 5.48 | (1.20) | 0.00 | (0.49) | 0.00 | 9.73 | 47.42 | |||
| SRZN | 4.41 | 0.94 | 0.19 | 0.82 | 4.44 | 13.34 | 34.29 | |||
| CGTX | 4.14 | (0.72) | 0.00 | (0.23) | 0.00 | 8.89 | 25.11 | |||
| COYA | 2.55 | (0.32) | 0.00 | 1.77 | 0.00 | 4.69 | 18.45 |
Cross Equities Net Income Analysis
Compare Atossa Genetics and related stocks such as Oncolytics Biotech, Tevogen Bio Holdings, and Greenwich Lifesciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONCY | (574.5 K) | (29 M) | (36.4 M) | (23.5 M) | (18.6 M) | (13.7 M) | (15.1 M) | (15.6 M) | (17 M) | (45.6 M) | (16.8 M) | (21 M) | (19.1 M) | (20.6 M) | (31.7 M) | (28.5 M) | (27.1 M) |
| TVGN | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | 4.4 M | (60.5 M) | (10.1 M) | (9.1 M) | (9.6 M) |
| GLSI | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.7 M) | (3.4 M) | (1.9 M) | (4.6 M) | (7.8 M) | (8.9 M) | (15.8 M) | (14.2 M) | (13.5 M) |
| TIL | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (37.7 M) | (156.8 M) | (223.2 M) | (156.1 M) | (74.1 M) | (66.7 M) | (70.1 M) |
| IMMX | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (1.1 M) | (24.4 M) | (8.2 M) | (15.4 M) | (21.6 M) | (19.5 M) | (18.5 M) |
| WHWK | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (3.5 M) | (110.1 M) | (60.5 M) | (65.8 M) | (63.7 M) | (57.3 M) | (60.2 M) |
| CLNN | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (277.3 K) | (16.2 M) | (19.3 M) | (9.7 M) | (29.9 M) | (49.5 M) | (39.4 M) | (35.5 M) | (33.7 M) |
| SRZN | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (32.6 M) | (52.5 M) | (27.7 M) | (43 M) | (63.6 M) | (57.2 M) | (60.1 M) |
| CGTX | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (10.1 M) | (11.7 M) | 757 K | (25.8 M) | (34 M) | (30.6 M) | (29 M) |
| COYA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.9 M) | (12.2 M) | (8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
Atossa Genetics and related stocks such as Oncolytics Biotech, Tevogen Bio Holdings, and Greenwich Lifesciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Atossa Genetics financial statement analysis. It represents the amount of money remaining after all of Atossa Genetics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Atossa Genetics Competitive Analysis
The better you understand Atossa Genetics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Atossa Genetics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Atossa Genetics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Atossa Genetics Competition Performance Charts
Five steps to successful analysis of Atossa Genetics Competition
Atossa Genetics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Atossa Genetics in relation to its competition. Atossa Genetics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Atossa Genetics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Atossa Genetics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Atossa Genetics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Atossa Genetics position
In addition to having Atossa Genetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Value Funds Thematic Idea Now
Small Value Funds
Funds or Etfs that invest in the undervalued stocks of small to mid-sized companies. The Small Value Funds theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.